🔗 Share this article World Health Organization Issues Concern Over Acute Shortage of Obesity Medications Under one in 10 patients eligible to benefit from obesity jabs including Wegovy have access to them, caution the WHO as it issues its inaugural recommendations on the medications. Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for broader and more equitable availability to this class of drugs. Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention. "Our new guidelines recognises that obesity is a chronic disease that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are major obstacles to broad availability to the jabs that can aid individuals in losing considerable weight, notes the body. GLP-1 Therapy Supply Crisis Even in the current most optimistic scenario, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of the global need, per the health organization. The guideline encourages countries and companies to expand access, via approaches such as voluntary licensing. A patent on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. How Weight-Loss Drugs Function The injections mimick a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals consume fewer calories. Patients typically begin shedding pounds within a few weeks of commencing the once-weekly jabs. Studies indicates people may put most of the weight back on a year later of discontinuing the treatment, because their normal hunger come back. Being overweight or obese elevates your likelihood for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Obesity affects people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
Under one in 10 patients eligible to benefit from obesity jabs including Wegovy have access to them, caution the WHO as it issues its inaugural recommendations on the medications. Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for broader and more equitable availability to this class of drugs. Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention. "Our new guidelines recognises that obesity is a chronic disease that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are major obstacles to broad availability to the jabs that can aid individuals in losing considerable weight, notes the body. GLP-1 Therapy Supply Crisis Even in the current most optimistic scenario, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of the global need, per the health organization. The guideline encourages countries and companies to expand access, via approaches such as voluntary licensing. A patent on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. How Weight-Loss Drugs Function The injections mimick a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals consume fewer calories. Patients typically begin shedding pounds within a few weeks of commencing the once-weekly jabs. Studies indicates people may put most of the weight back on a year later of discontinuing the treatment, because their normal hunger come back. Being overweight or obese elevates your likelihood for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Obesity affects people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.